Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.